Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens

Gynecologic Oncology

Volumn 65, Issue 3, 1997, Pages 434-436

  Markman, Maurie ^a   Kennedy, Alexander ^a   Webster, Kenneth ^a   Kulp, Barbara ^a   Peterson, Gertrude ^a   Belinson, Jerome ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0031172815     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4708     Document Type: Article

References (14)

1. 1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
2. 2. Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993
3. 3. Fisher RI, DeVita VT, Hubbard SP, Simon R, Young RC: Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 90:761-763, 1979
4. 4. Batist G, Ihde DC, Zabell A, Lichter AS, Veach SR, Cohen MH, Carney DN, Bunn PA: Small-cell carcinoma of the lung: reinduction therapy after late relapse. Ann Intern Med 98:472-474, 1983
5. 5. Seltzer V, Vogl S, Kaplan B: Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. Gynecol Oncol 21:167-176, 1985
6. 6. Gershenson DM, Kavanagh JJ, Copeland LJ, Stringer A, Morris M, Wharton JT: Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol 73:798-802, 1989
7. 7. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
8. 8. Gore ME, Fryatt I, Wiltshaw E, Dawson T: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207-211, 1990
9. 9. Markman M: A proposal to use CA-125 to evaluate activity of new antineoplastic agents in ovarian cancer. Gynecol Oncol 51:297-298, 1993
10. 10. Rustin GJS, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14:1545-1551, 1996
11. 11. Berkowitz RS: CA 125 measurement in epithelial ovarian cancer: 10-year anniversary of clinical investigation. Gynecol Oncol 49:1-2, 1993
12. 12. Makar APH, Kristensen GB, Bormer OP, Trope CG: Serum CA 125 levels allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol 49:73-79, 1993
13. 13. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
14. 14. Markman M, Hakes T, Barakat R, Curtin J, Almadrones L, Hoskins W: Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on NCI Treatment Referral Center Protocol 9103: paclitaxel in refractory ovarian cancer. J Clin Oncol 14:796-799, 1996